During the past decade, Instituto de Infectologia Emilio Ribas conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 7 clinical trials were completed, i.e. on average, 58.3% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 3 clinical trials were completed. i.e. 27.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Instituto de Infectologia Emilio Ribas" #1 sponsor was "National Institute of Allergy and Infectious Diseases (NIAID)" with 6 trials, followed by "Janssen Vaccines & Prevention B.V." with 3 trials sponsored, "Bristol-Myers Squibb" with 2 trials sponsored, "Boehringer Ingelheim" with 1 trials sponsored and "Butantan Institute" with 1 trials sponsored. Other sponsors include 6 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Instituto de Infectologia Emilio Ribas" #1 collaborator was "Gilead Sciences" with 2 trials as a collaborator, "Chiron Corporation" with 1 trials as a collaborator, "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" with 1 trials as a collaborator, "Federal University of Minas Gerais" with 1 trials as a collaborator and "Fundação de Amparo à Pesquisa do Estado de São Paulo" with 1 trials as a collaborator. Other collaborators include 17 different institutions and companies that were collaborators in the rest 27 trials.

According to Clinical.Site data, the most researched conditions in "Instituto de Infectologia Emilio Ribas" are "HIV Infections" (9 trials), "COVID-19" (4 trials), "Hepatitis B" (2 trials), "Acute Respiratory Infection" (1 trials) and "COVID-19 Pneumonia" (1 trials). Many other conditions were trialed in "Instituto de Infectologia Emilio Ribas" in a lesser frequency.

Most popular intervention types in "Instituto de Infectologia Emilio Ribas" are "Drug" (15 trials), "Biological" (5 trials), "Other" (4 trials), "Diagnostic Test" (1 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Ad26.COV2.S" (2 trials), "Ad26.Mos4.HIV" (1 trials), "Adefovir" (1 trials) and "Adsorbed COVID-19 (inactivated) Vaccine" (1 trials). Other intervention names were less common.

The vast majority of trials in "Instituto de Infectologia Emilio Ribas" are 24 trials for "All" genders.

Currently, there are NaN active trials in "Instituto de Infectologia Emilio Ribas". undefined are not yet recruiting, 2 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Instituto de Infectologia Emilio Ribas, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Instituto de Infectologia Emilio Ribas, 1 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 15 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".